Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon-α2b in Moderate COVID-19
NCT04480138Phase 2Terminated
- Sponsor
- Zydus Lifesciences Limited
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in coronavirus disease 2019 (COVID-19), sponsored by Zydus Lifesciences Limited. Started Aug 2020; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04480138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480138.